Fachbereich Veterinärmedizin



    Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza (2008)

    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Rosas, Cristina
    Van de Walle, Gerlinde R
    Metzger, Stephan M
    Hoelzer, Karin
    Dubovi, Edward J
    Kim, Sung G
    Parrish, Colin R
    Osterrieder, Nikolaus
    Vaccine; 26(19) — S. 2335–2343
    ISSN: 0264-410x
    DOI: 10.1016/j.vaccine.2008.02.064
    Pubmed: 18407383
    Institut für Virologie

    Robert-von-Ostertag-Str. 7-13
    Gebäude 35
    14163 Berlin
    +49 30 838 51833

    Abstract / Zusammenfassung

    In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce virus spread.